Shares of COFOE MEDICAL (HKEX: 01187) rose more than 8% in late trading. At the time of writing, the stock was up 8.23% to HK$33.54, with a turnover of HK$38.64 million.

The company recently disclosed its full-year 2025 and first-quarter 2026 financial results. According to analysis, COFOE MEDICAL achieved operating revenue of 3.387 billion yuan in 2025, representing a year-on-year increase of 13.56%. Net profit attributable to shareholders reached 372 million yuan, up 19.20% from the previous year.

For the first quarter of 2026, the company reported revenue of 1.012 billion yuan, a significant surge of 37.22% year-on-year. Net profit attributable to shareholders was 107 million yuan, growing by 17.08%, continuing its positive growth trajectory.

Key Product and Strategy Developments

On the product front, revenue from the company's respiratory support segment in the second half of 2025 saw robust growth of 80.18% year-on-year. COFOE MEDICAL launched its new-generation AI-powered ventilator, the C11, in 2026. The company is also slated to introduce a new high-end ventilator model by the end of 2026, further enriching its product portfolio. It is projected that ventilator sales will achieve multiple-fold growth in 2026.

Regarding international expansion, in late December 2025, the company completed a strategic investment in Ronshin Medical. Ronshin Medical holds a leading position in the global digital healthcare market for respiratory health, with its products available in over 200 countries and regions. This strategic move is expected to significantly accelerate COFOE MEDICAL's efforts to expand its ventilator products into international markets.